GW PHARMACEUTICALS PLC Net Change in Cash
GW PHARMACEUTICALS PLC reported Net Change in Cash of -$28.65 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-03.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2021-05-03
- GW PHARMACEUTICALS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-03-31 was -$28.65M.
- GW PHARMACEUTICALS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2020-03-31 was -$36.00M.
- GW PHARMACEUTICALS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2019-03-31 was -$69.83M.
- GW PHARMACEUTICALS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2018-12-31 was $236.58M, a 0.21% decline year-over-year.
- GW PHARMACEUTICALS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was -$50.18M.
- GW PHARMACEUTICALS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2019 was -$54.56M.
- GW PHARMACEUTICALS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2018 was $32.76M.
- GW PHARMACEUTICALS PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2017 was -$161.29M, a 225.86% decline from fiscal 2016.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2021-03-31 | -$28.65M 10-Q · filed 2021-05-03 | |||
| 2020-12-31 | -$50.18M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | -$56.60M 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | -$59.38M 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | -$36.00M 10-Q · filed 2021-05-03 | |||
| 2019-12-31 | -$54.56M 10-K · filed 2021-02-26 | |||
| 2019-09-30 | -$36.81M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$7.81M 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | -$69.83M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $236.58M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | -$204.31M 10-Q · filed 2019-11-06 | $32.76M 10-K · filed 2021-02-26 | ||
| 2018-06-30 | -$119.29M 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | -$71.99M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $237.07M 10-K · filed 2021-02-26 | |||
| 2017-09-30 | -$161.29M 10-K · filed 2020-02-27 | |||
| 2016-09-30 | $128.15M 10-KT · filed 2019-02-28 |